Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor

Journal of Immunology

Volumn 164, Issue 5, 2000, Pages 2776-2781

  Croxford, J Ludovic ^a   Triantaphyllopoulos, Kostas A ^b   Neve, Richard M ^b   Feldmann, Marc ^b   Chernajovsky, Yuti ^b   Baker, David ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; TUMOR NECROSIS FACTOR RECEPTOR; VIRUS VECTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CELL IMMORTALIZATION; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GENE THERAPY; IMMUNOCYTOCHEMISTRY; INFLAMMATORY DISEASE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS;

EID: 0034162594     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.5.2776     Document Type: Article

References (46)

1. Tracey, K. J., H. Wei, K. R. Manogue, Y. Fong, D. G. Hesse, H. T. Nguyen, G. C. Kuo, B. Beutler, R. S. Cotran, A. Cerami, and S. F. Lowry. 1988. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J. Exp. Med. 167:1211.
2. Brosnan, C.F., K. Selmaj, and C. S. Raine. 1988. Hypothesis: a role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis. J. Neuroimmunol. 18:87.
3. Selmaj, K., and C. S. Raine. 1988. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro, Ann. Neurol. 23:339.
4. Barten, D.M., and N. H. Ruddle. 1994. Vascular cell adhesion molecule-1 modulation by tumor necrosis factor in experimental allergic encephalomyelitis. J. Neuroimmunol. 51:123.
5. Ruddle, N. H., C. M. Bergman, K. M. McGrath, E. G. Lingenheld, M. L. Grunnet, S. J. Padula, and R. B. Clark. 1990. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1193.
6. Selmaj, K., C. S. Raine, and A. H. Cross. 1991. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neurol. 30:694.
7. Baker, D., D. Butler, B. J. Scallon, J. K. O'Neill, J. L. Turk, and M. Feldmann. 1994. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur. J. Immunol. 24:2040.
8. Steinman, L. 1997. Some misconceptions about understanding autoimmunity through experiments with knockouts. J. Exp. Med. 185:2039.
9. Croxford, J. L., K. Triantaphyllopoulos, O. L. Podhajcer, M. Feldmann, D. Baker, and Y. Chernajovsky. 1998. Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J. Immnnol. 160:5181.
10. Brenner, M. K., D. R. Rill, M. S. Holladay, H. E. Heslop, R. C. Moen, M. Buschle, R. A. Krance, V. M. Santana, W. F. Anderson, and J. N. Ihle. 1993. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet. 342:1134.
11. Levivier, M., S. Przedborski, C. Bencsics, and U. J. Kang. 1995. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 15:7810.
12. Fitoussi, N., I. Sotnick-Barkai, C. Turnatore, U. Herzberg, and G. Yadid, 1998. Dopamine turnover and metabolism in the striatum of parkinsonian rats grafted with genetically-modified human astrocytes. Nenroscience 85:405.
13. Baker, D., J. K. O'Neill, S. E. Gschmeissner, C. E. Wilcox, C. Butter, and J. L. Turk. 1990. Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice. J. Neuroimmunol. 28:261.
14. O'Neill, J.K., D. Baker, A. N. Davison, K. K. Maggon, B. D. Jaffee, and J. L. Turk. 1992. Therapy of chronic relapsing experimental allergic encephalomyelitis and the role of the blood-brain barrier; elucidation by the action of Brequinar sodium. J. Neuroimmunol. 38:53.
15. Almazan, G., and R. McKay. 1992. An oligodendrocyte precursor cell line from rat optic nerve. Brain Res. 279:367.
16. Neve, R., M. Kissonerghis, J. Clark, M. Feldmann, and Y. Chernajovsky. 1996. Expression of an efficient small molecular weight tumour necrosis factor/lymphotoxin antagonist. Cytokine 8:365.
17. Triantaphyllopoulos, K.A., J. L. Croxford, D. Baker, and Y. Chernajovsky. 1998. Cloning and expression of marine IFNβ and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis. Gene Ther. 5:253.
18. Chernajovsky, Y. Systemic gene therapy for arthritis. 1999. In Discovery, Development and Evaluation of New Anti-Arthritic Drugs. Drugs of Today, Vol. 3. Evans, C., and P. D. Robbins, eds. Prous Science, Barcelona, pp. 361-377.
19. Körner, H., F. A. Lemckert, G. Chaudhri, S. Etteldorf, and J. D. Sedgwick. 1997. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J. Exp. Med. 186:1585.
20. Selmaj, K., W. Papierz, A. Glabinski, and T. Kohno. 1995. Prevention of chronic relapsing experimental allergic encephalomyelitis by soluble tumor necrosis factor receptor I. J. Neuroimmunol. 56:135.
21. Selmaj, K., A. Walczak, M. Mycko, T. Berkowitz, T. Kohno, and C. S. Raine. 1998. Suppression of experimental autoimmune encephalomyelitis with a TNF binding protein (TNFbp) correlates with down-regulation of VCAM-1/VLA-4. Eur. J. Immunol. 28:2035.
22. Barten, D. M., and N. H. Ruddle. 1994. Vascular cell adhesion molecule-1 modulation by tumor necrosis factor in experimental allergic encephalomyelitis. J. Neuroimmunol. 151:123.
23. Körner, H., F. A. Lemckert, G. Chaudhri, S. Etteldorf, and J. D. Sedgwick. 1997. Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system. Eur. J. Immunol. 27:1973.
24. Allen, S. J., D. Baker, J. K. O'Neill, A. N. Davison, and J. L. Turk. 1993. Isolation and characterization of cells infiltrating the spinal cord during the course of chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse. Cell. Immunol. 146:335.
25. Hofman, F. M., D. R. Hinton. K. Johnson, and J. E. Merril. 1989. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 170:607.
26. Selmaj, K., C. S. Raine, B. Cannella, and C. F. Brosnan. 1991. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 87:949.
27. Chofflon, M., C. Juillard, P. Juillard, G. Gauthier, and G. E. Grau. 1992. Tumor necrosis factor a production as a possible predictor of relapse in patients with multiple sclerosis. Eur .Cytokine. Netw. 3:523.
28. Spuler, S., T. Yousry, A. Scheller, R. Voltz, E. Holler, M. Hartmann, M. Wick, and R. Hohlfeld. 1996. Multiple sclerosis: prospective analysis of TNF-α and p55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity. J. Neuroimmunol. 66:57.
29. Elliott, M. J., R. N. Maini, M. Feldmann, J. R. Kalden, C. Antoni, J. S. Smolen, B. Leeb, F. C. Breedveld, J. D. Macfarlane, H. Bijl, and J. N. Woody. 1994. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105.
30. Van Dullemen, H. M., S. J. H. Van Deventer, D. W. Hommes, H. A. Bijl, J. Jansen, G. N. J. Tytgal, and J. Woody. 1995. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2), Gastroenterology 109:129.
31. Fisher, C. J., J. M. Agosti, S. M. Opal, S. F. Lowry, R. A. Balk, J. C. Sadoff, E. Abraham, R. M. H. Schein, and E. Benjamin. 1996. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N. Engl. J. Med. 334:1697.
32. Abraham, E., A. Anzueto, G. Gutierrez, S. Tessler, G. San Pedro, R. Wunderink, A. Dal Nogare, S. Nasraway, S. Berman, R. Cooney, et al. 1998. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 351:929.
33. Martin, R., N. H. Ruddle, S. Reingold, and D. A. Hafler. 1998. T helper cell differentiation in multiple sclerosis and autoimmunity. Immunol. Today 19:495.
34. Carballo, E., W. S. Lai, and P. J. Blackshear 1998. Feedback inhibition of macrophage tumor necrosis factor-α production by tristetraprolin. Science 281:1001.
35. Di Santo, E., M. Sironi, P. Pozzi, P. Gnocchi, A. M. Isetta, A. Delvaux, M. Goldman, A. Marchant, and P. Ghezzi. 1995. Interleukin-10 inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin-1β production in the brain without affecting the activation of the hypothalamus-pituitary-adrenal axis. Neuroimmunomodulation 2:149.
36. Wang, J., X. Cao, W. Zhang, T. Ye, and K. Tani. 1996. Treatment of leukemia with fibroblast-mediated interferon-α gene therapy alone or in combination with doxorabicin. Leuk. Res. 20:379.
37. Fisher, L. J., H. K. Raymon, and F. H. Gage. 1993. Cells engineered to produce acetylcholine: therapeutic potential for Alzheimer's disease. Ann. NY Acad. Sci. 695:278.
38. Glick, R. P., T. Lichtor, A. Mogharbel, C. A. Taylor, and E. P. Cohen. 1997. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma. Neurosurgery 41:898.
39. Triantaphyllopoulos. K., R. O. Williams, H. Tailor, and Y. Chernajovsky. 1999. Amelioration of collagen-induced arthritis and suppression of IFN γ. IL-12 and TNF production by IFN β gene therapy. Arthritis Rheum. 42:90.
40. Pelletier, J. P., J. P. Caron, C. Evans, P. D. Robbins, H. I. Georgescu, D. Jovanovic, J. C. Fernandes, and J. Martel-Pelletier. 1997. In vivo suppression of early experimental osteoarthritis hy interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum. 40:1012.
41. Bakker, A. C., L. A. Joosten, O. J. Arntz, M. M. Helsen, F. A. van der Loo, and W. B. van den Berg. 1997. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum. 40:893.
42. O'Leary, M. T., and W. F. Blakemore. 1997. Use of a rat Y chromosome probe to determine the long-term survival of glial cells transplanted into areas of CNS demyelination. J. Neurocytol. 26:191.
43. Mathisen, P. M., M. Yu, J. M. Johnson, J. A. Drazba, and V. K. Tuohy. 1997. Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells. J. Exp. Med. 186:159.
44. Shaw, M. K., J. B. Lurens, A. Dhawan, R. DalCanto, H. Y. Tse, A. B. Tran, C. Bonpane, S. L. Eswaran, S. Brocke, N. Sarvetnick, L. Steinman, G. P. Nolan, and C. G. Fathman. 1997. Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis J. Exp. Med 185:1711.
45. Chen, L. Z., G. M. Hochwald, C. Huang, G. Dakin, H. Tao, C. Cheng, W. J. Simmons, G. Dranoff, and G. J. Thorbecke. 1998. Gene therapy in allergic encephatomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-β1. Proc. Natl. Acad. Sci. USA 95:12516.
46. Aebischer, P., M. Schluep, N. Doglon, J. Joseph, L. Hirt, B. Heyd, M. Goddard, J. P. Hammang, A. D. Zurn, A. C. Kato, F. Regli, and E. E. Baetge. 1996. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneie cells in amyotrophic lateral sclerosis patients. Nat. Med. 2:696.